Late Complications of Allogenic Stem Cells Transplantation in Leukaemia
10.1007/s13770-018-0157-3
- Author:
Sharmilla KANAGASUNDRAM
1
;
Farhanaz AMINI
Author Information
1. Department of Psychological Medicine, Faculty of Medicine, University Malaya, 50603 Kuala Lumpur, Malaysia. sharmilla_kanagasundram@yahoo.com
- Publication Type:Review
- Keywords:
Allogenic stem cells;
Chronic graft;
Late complications;
Leukaemia
- MeSH:
Azoospermia;
Bronchiolitis Obliterans;
Cardiovascular Diseases;
Cross-Sectional Studies;
Depression;
Follow-Up Studies;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Hypothyroidism;
Male;
Necrosis;
Prevalence;
Prospective Studies;
Retrospective Studies;
Stem Cell Transplantation;
Stem Cells
- From:
Tissue Engineering and Regenerative Medicine
2019;16(1):1-9
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure leukaemia. However, long term complications of post transplantation interfere with the patients’ full recovery. The objective of this review was to identify the various long term complications and to assess their individual prevalences. METHODS: Electronic databases including PubMed, Google Scholar and Cochrane were searched for years 2004-2017. The keywords used were leukaemia, allogenic stem cell transplantation, prevalence, side effects, long term, delayed, adverse effects, complications and outcome. RESULTS: A total of ten articles were included for analysis. There were 5 prospective studies, 3 retrospective studies and 2 cross sectional studies. A total of 40,069 patients, (20,189 males and 17,191 females) participated in these 10 studies. The gender of 2689 patients were not disclosed. Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). The prevalence of azoospermia was 71.1% and depression, 18%. For the latter two conditions no time limit was available. Follow up duration ranged from 2 years till 30 years post HSCT. CONCLUSION: While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure.
